Please login to the form below
Oseni
This page shows the latest Oseni news and features for those working in and with pharma, biotech and healthcare.
Forest Labs agrees $1.46bn deal to buy Furiex
Furiex also has a stable of marketed drugs for diabetes including Nesina (alogliptin) and fixed-dose combination therapies Oseni/Liovel (alogliptin/pioglitazone) and Kazan (alogliptin/metformin), which are sold by Takeda,
Latest news
-
FDA investigates pancreas risk of diabetes drugs
Newer DPP-4 inhibitors Tradjenta (linagliptin) from Boehringer Ingelheim and Takeda's alogliptin-based medicines (Nesina, Kazano and Oseni) are also affected.
-
Takeda gets FDA approval for alogliptin franchise in diabetes
Comprises Nesina, Oseni and Kazano. Takeda was celebrating at the end of last week after the FDA granted approval to three of its diabetes drug candidates. ... The US agency approved Takeda's DPP-4 inhibitor Nesina (alogliptin) - along with two
More from news
Approximately 1 fully matching, plus 2 partially matching documents found.
COVID-19 Updates and Daily News
Featured jobs
- FREELANCE Medical Writer, Senior Medical Writer, Principal Medic...
-
Highly Competitive Day Rate, Bonus &Benefits
- Senior Account / Programme Manager - MedComms - Buckinghamshire
-
Highly Competitive Remuneration packages
- Freelance Medical Writer - Creative Healthcare Comms - 2 month t...
-
Excellent Day Rate
- Senior Leadership Role – Medical Communications – North West
-
Highly Competitive Salary, Bonus &Benefits
- Senior Content Editor - Biotechnology
-
Salary TBC
-
Account Management
-
Competitive Salary Offered
- Freelance Account Manager - Creative Healthcare Comms - Immediat...
-
Excellent Day Rate
- Novavax seeks FDA emergency approval for COVID-19 vaccine by May
- UPDATE: AZ/Oxford University COVID-19 vaccine gets EU approval
- J&J looks ahead at potential flu therapy after approval of its COVID-19 vaccine
- Bayer’s finerenone scores FDA priority review for chronic kidney disease
- Sanofi pays $160m upfront to acquire Tidal Therapeutics
- UK study finds Pfizer/BioNTech, AZ/Oxford vaccines reduce severe COVID-19 in older people
- US pauses rollout of J&J’s COVID-19 vaccine amid reports of rare blood clots
- Lilly’s RET inhibitor Retevmo shows early promise in new cancer types
- Oxford study finds standard asthma medication improves recovery time in COVID-19 patients
- FDA approves new self-injection administration for Xolair
- Opdivo plus chemotherapy increases response in pre-surgery NSCLC patients
- Scientific meetings: leveraging on-site, virtual, on-demand and enduring materials
PMHub
W2O Group
W2O Group is an integrated marketing agency with expertise in brand and digital strategy, creative development and communications services. We...
Latest intelligence
- Want to give perfect client service? Tough luck, you’re human
- In this article an ex-client of mine, Liz Skrbkova, and I explore the (unhelpful) pressures of trying to perfect the client-agency relationship...
- WHITE PAPER: Why do men die younger?
- It’s a commonly accepted fact that women outlive men. Wherever you live, there’s a good chance that men will die on average eight years earlier than women. Is this an...
- 3 tips to show patient diversity in your clinical trial materials
- Here are some useful tips to help get your hands on authentically diverse stock photos....
Quick links
Infographics
